• Store

Renewal Program

RenewalTo ensure that providers stay current in their knowledge of safe chemotherapy and biotherapy administration, APHON requires approved Providers to renew their status every three years.

This is an important part of the Provider Program so that all Providers keep pace with the ever changing advancement in medicine and technology. This online program asks participants to read updated administration material, take a posttest, and complete an evaluation. (You will be allowed to retake the posttest only one time if you fail on the first try.)

2016 Provider Renewal

The 2016 Pediatric Chemotherapy/Biotherapy Renewal is now closed. Providers that have a December 31, 2016 expiration date and failed to complete the renewal program must site for the 2-day course in order to become a current Pediatric Chemotherapy/Biotherapy Provider. 

Content of the Program

  • Emerging Therapies in Pediatric Oncology
  • Typhlitis and Sinusoidal Obstruction Syndrome as Treatment-Associated Toxicities
  • Medication Adherence in Childhood Acute Lymphoblastic Leukemia
  • Care of the Patient Receiving Radiation Therapy

The renewal exam consists of 25 questions and you must achieve a minimum score of 80% to pass. If you are unsuccessful on your first attempt, you will be permitted to retake the exam at no additional cost. If you do not achieve a passing score after two attempts you will be required to take the 2-day provider course again. APHON will try to contact providers in advance of the renewal deadlines, but providers are responsible for maintaining their own status. Providers are not eligible to renew nor will they be able to access the posttest until approximately 8 weeks prior to their expiration date.

Renewal Fee Structure


Member: $55
Nonmember: $75


Member: $75
Nonmember: $95

Renewal Dates

The dates for provider renewals are as follows (please refer to your provider card for the issue date):

Provider Card Issue Date

Renewal Deadlines

1/1/2015-12/31/2015 12/31/2017
1/1/2016-12/31/2016 12/31/2018

Providers that previously completed the renewal process may access their CNE certificate here. You will be required to login using your APHON website ID and password.

Accreditation and Disclaimer

Pharmacology Content

This program may be also recognized for the amount of 0.34 hours of pharmacology content indicated as calculated by the APHON Pediatric Chemotherapy/Biotherapy Provider Program Committee. APHON recommends that attendees retain a copy of this web page for supportive documentation. Please note that you may not apply CNE toward pharmacology content. The content may be applied in only one area, nursing contact hours or pharmacology content.

Official ONCC Statement and Disclaimer

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

CPHON® Blueprint

  • Treatment Modalities

BMTCN Blueprint

  • Preparative Regimens and Stem Cell Infusion

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program. Have questions regarding the CPHON® ILNA Coding? Please visit the ONCC website or call them toll-free at 877.769.ONCC (US and Canada only)

Accreditation Statement

The Association of Pediatric Hematology/Oncology Nurses (APHON) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


A staff member, volunteer, or family member who has an affiliation with a commercial company must declare that relationship in advance of involvement with an education activity that could be used as a forum to promote the interest of that company and its products. There are no disclosures to report for this activity.